LGD 4033 Ligandrol Capsules

LGD 4033 Ligandrol (Capsule Form)

LGD-4033 (Ligandrol) is a SARM that is studied for its high-affinity interaction with androgen receptors in muscle and bone tissues. In experimental and preclinical research, it demonstrates selective activation of receptor-mediated pathways involved in protein synthesis, cellular growth, and bone metabolism. 

It remains an investigational compound with no approved medical use, and its full biological profile continues to be evaluated in controlled research conditions.

Mechanism of Action of LGD 4033

LGD-4033 functions by selectively binding to androgen receptors in muscle and bone tissues in models. It activates receptor-mediated gene transcription pathways involved in protein synthesis and cellular growth in experimental models

Chemical Properties of LGD 4033

• CAS Number is stated as 1165910-22-4
• Molar Mass is 338.253 g·mol−1
• It has a Chemical Formula of C14H12F6N2O
• IUPAC Name is 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
• Also known by Synonyms as VK5211; LGD-4033.

Note: For researchers looking to expand their studies, we also offer LGD 4033 + MK 677 Capsules and LGD4033 + RAD140 + YK11 Capsules. Additionally, our SARMs Capsules Collection provides a range of research compounds in convenient capsule form. Explore our inventory to find research materials suited to your needs.

Research Findings on LGD 4033 

LGD-4033 is investigated in pharmacokinetic and metabolic studies to understand its absorption, distribution, metabolism, and elimination in biological systems. These studies help characterize its stability, metabolic pathways, and compound behavior in research. 

Data from National Institutes of Health resources show that it is used to examine how selective androgen receptor modulators interact with target receptors compared to other nuclear receptors. This supports research into molecular binding affinity, receptor specificity, and the development of targeted signaling models in experimental systems.

Why Choose BehemothLabz to Buy Ligandrol (LGD-4033) Capsules? 

When sourcing LGD-4033 capsules for laboratory research, it is important to evaluate both the compound and the supplier carefully. Variations in identity, purity, or stability can affect experimental consistency and outcomes. For this reason, selecting a reliable source with clear documentation and verified standards is essential in research settings.

Behemoth labz offer Ligandrol for sale. You can buy LGD 4033 in encapsulated form intended for controlled laboratory use at our online store. These compounds are handled with a focus on maintaining integrity and consistency. Suppliers in this field typically perform internal or third-party testing to confirm identity and purity, supporting reproducibility and reliability in experimental work.

BehemothLabz Disclaimer

Please make sure you go through the Terms and Conditions, and please familiarize yourself with it as they are important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.

Buying the product means you agree to our Terms and Conditions. You can contact our awesome customer service team at support@behemothlabz.com if you are not fully satisfied with the product. Customer satisfaction is our number one priority!

ATTENTION: All Behemoth Labz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Reference Links

PubChem. (2026). Vk-5211. Nih.gov; PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Vk-5211

Basaria, S., Collins, L., Dillon, E. L., Orwoll, K., Storer, T. W., Miciek, R., Ulloor, J., Zhang, A., Eder, R., Zientek, H., Gordon, G., Kazmi, S., Sheffield-Moore, M., & Bhasin, S. (2010). The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. The Journals of Gerontology: Series A, 68(1), 87–95. https://doi.org/10.1093/gerona/gls078

Christiansen, A. R., Lipshultz, L. I., Hotaling, J. M., & Pastuszak, A. W. (2020). Selective androgen receptor modulators: the future of androgen therapy? Translational Andrology and Urology, 9(S2), S135–S148. https://doi.org/10.21037/tau.2019.11.02

1st Party COA

3rd Party COA

Please click here to access instructions on how to make a payment.